✦ LIBER ✦

Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis

✍ Scribed by Richard A. Rudick; Diane L. Cookfair; Nancy A. Simonian; Richard M. Ransohoff; John R. Richert; Lawrence D. Jacobs; Robert M. Herndon; Andres M. Salazar; Jill S. Fischer; Carl V. Granger; Donald E. Goodkin; Jack H. Simon; David M. Bartoszak; Dennis N. Bourdette; Jonathan Braiman; Carol M. Brownscheidle; Michael E. Coats; Stanley L. Cohan; David S. Dougherty; Revere P. Kinkel; Michele K. Mass; Frederick E. Munchsauer; Kathy O'Reilly; Roger L. Priore; Patrick M. Pullicino; Barbara J. Scherokman; Karl Wende; Bianca Weinstock-Guttman; Ruth H. Whitham

Book ID: 114138252
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 174 KB
Volume: 93
Category: Article
ISSN: 0165-5728
DOI: 10.1016/s0165-5728(98)00174-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination of IFNβ-1a (Avonex®) and myc

Combination of IFNβ-1a (Avonex®) and mycophenolate mofetil (Cellcept®) in multiple sclerosis

✍ P. Vermersch; N. Waucquier; E. Michelin; H. Bourteel; T. Stojkovic; D. Ferriby; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 467 KB

Quantitative differences in the immunomo

Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients

✍ George P. Christophi; Jennifer A. Christophi; Ross C. Gruber; Cornelia Mihai; Lu 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 173 KB

fMRI changes in relapsing-remitting mult

fMRI changes in relapsing-remitting multiple sclerosis patients complaining of fatigue after IFNβ-1a injection

✍ Maria A. Rocca; Federica Agosta; Bruno Colombo; Domenico M. Mezzapesa; Andrea Fa 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB

## Abstract If fatigue in multiple sclerosis (MS) is related to an abnormal activation of the sensorimotor brain network, the activity of such a network should vary with varying fatigue. We studied 22 patients treated with interferon beta 1a (IFNβ‐1a; Avonex, Biogen, Cambridge, MA) with no fatigue

A prospective, open-label treatment tria

A prospective, open-label treatment trial to compare the effect of IFN -1a (Avonex(R)), IFN -1b (Betaseron(R)), and glatiramer acetate (Copaxone(R)) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy

✍ Khan, O. A; Tselis, A. C; Kamholz, J. A; Garbern, J. Y; Lewis, R. A; Lisak, R. P 📂 Article 📅 2001 🏛 SAGE Publications 🌐 English ⚖ 95 KB

Magnetic resonance studies of intramuscu

Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis

✍ Dr Jack H. Simon; Lawrence D. Jacobs; Marilyn Campion; Karl Wende; Nancy Simonia 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 862 KB

OPL102 Subgroup analyses from SENTINEL:

OPL102 Subgroup analyses from SENTINEL: a randomized controlled trial of natalizumab (Tysabri®) and interferon beta-1a (AVONEX®) in relapsing multiple sclerosis (MS)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 130 KB